News

Filter

Current filters:

Optimer Pharmaceuticals

1 to 9 of 14 results

AstraZeneca inks deal for Optimer's fidaxomicin in Latin America

04-12-2012

USA-based Optimer Pharmaceuticals (Nasdaq: OPTR) says it has executed an exclusive agreement with Anglo-Swedish…

Antibiotics and Infectious diseasesAstraZenecafidaxomicinLicensingOptimer PharmaceuticalsPharmaceuticalSouth America

Optimer Pharma to sell remaining stake in Optimer Biotech for $60 million

08-10-2012

San Diego, USA-based Optimer Pharmaceuticals (Nasdaq: OPTR) yesterday announced the sale of its stake…

BiotechnologyDificidMergers & AcquisitionsOptimer BiotechnologyOptimer PharmaceuticalsPharmaceutical

Optimer earns 10 million-euro milestone as Astellas debuts Dificlir in Europe

11-06-2012

USA-Based Optimer Pharmaceuticals (Nasdaq: OPTR) says that it is set to receive 10 million euros ($12.5…

Antibiotics and Infectious diseasesAstellas PharmaDificlirEuropeFinancialLicensingOptimer PharmaceuticalsPharmaceutical

Senior exec changes actual or sought at Johnson & Johnson, AstraZeneca and Optimer

10-04-2012

US health care giant Johnson & Johnson (NYSE: JNJ) said on Monday that Sherilyn (Sheri) McCoy, vice chairman…

AstraZenecaJohnson & JohnsonManagementOptimer PharmaceuticalsPharmaceutical

Optimer Pharma could earn $90 million from new Astellas deal

30-03-2012

US firm Optimer Pharmaceuticals (Nasdaq: OPTR) has entered into a second deal with Japanese drug major…

Antibiotics and Infectious diseasesAsia-PacificAstellas PharmaDificidfidaxomicinLicensingOptimer PharmaceuticalsPharmaceutical

Astellas and Optimer’s C. difficile drug cleared in Europe

13-12-2011

Following an earlier positive recommendation from a European Medicines Agency advisory panel (The Pharma…

Antibiotics and Infectious diseasesAstellas PharmaDificidDificlirEuropeOptimer PharmaceuticalsPharmaceuticalRegulation

Optimer/Cubist’s Dificid poised to challenge Vancocin usage in C. difficile treatment; report

14-09-2011

Less than half of surveyed infectious disease (ID) specialists and only 6% of surveyed internists demonstrated…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDificidMarkets & MarketingNorth AmericaOptimer PharmaceuticalsPharmaceuticalVancocin

1 to 9 of 14 results

Back to top